The neuroprotective effect of memantine during cardiopulmonary bypass

The neuroprotective effect of memantine during cardiopulmonary bypass in patients that are candidate for cardiac surgery

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200502047276N1

Enrollment

Registered

2020-06-02

Start date

2020-06-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart diseases. Chronic ischemic heart disease

Interventions

Intervention 1: Intervention group: patients that received memantine 10 mg/bid for 3 days before surgery. Intervention 2: Control group: will not receive any medication or placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients that are candidate for open heart surgery Age between 18 to 80 years

Exclusion criteria

Exclusion criteria: Acute or chronic renal failure (AKI stage 4 or 5) Creatinine clearance less than 30 ml/min Moderate to severe hepatic failure Autoimmune disease Alzheimer or dementia History of memantine consumption within last 6 months History of seizure, CVA, or psychiatric disorders

Design outcomes

Primary

Measure	Time frame
S100B protein level during preoperative and postoperative courses. Timepoint: before surgery, after cardiopulmonary bypass weaning, 6 hours after surgery, 24 hours after surgery. Method of measurement: Enzyme linked immunoassay (ELISA), Human Protein S100-B(S100B)ELISA Kit.	—

Secondary

Measure	Time frame
Neurological deficits. Timepoint: Post-operation up to 30 days. Method of measurement: Neurological examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Sanei Motlagh

Mazandaran University of Medical Sciences

alireza.scts@yahoo.com+98 11 3331 4755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026